Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies
Платформа мультиплексного редактирования генома и производства T-клеток для готовых к применению адоптивных T-клеточных иммунотерапевтических препаратов
2015-07-16
SCID: 54.1/xjfqrwfj
Discuss with AI
CAR T-cell immunotherapyCD19 CARMultiplex gene editingOff-the-shelf T-cell therapyTALEN-mediated genome editing
Figures from the paper
Abstract (AI)
Adoptive immunotherapy using autologous T cells endowed with chimeric antigen receptors (CAR) has emerged as a powerful means of treating cancer. However, a limitation of this approach is that autologous CAR T cells must be generated on a custom-made basis. Here we show that electroporation of transcription activator-like effector nuclease (TALEN) mRNA allows highly efficient multiplex gene editing in primary human T cells. We use this TALEN-mediated editing approach to develop a process for the large-scale manufacturing of T cells deficient in expression of both their αβ T-cell receptor (TCR) and CD52, a protein targeted by alemtuzumab, a chemotherapeutic agent. Functionally, T cells manufactured with this process do not mediate graft-versus-host reactions and are rendered resistant to destruction by alemtuzumab. These characteristics enable the administration of alemtuzumab concurrently or prior to engineered T cells, supporting their engraftment. Furthermore, endowing the TALEN-engineered cells with a CD19 CAR led to efficient destruction of CD19(+) tumor targets even in the presence of the chemotherapeutic agent. These results demonstrate the applicability of TALEN-mediated genome editing to a scalable process, which enables the manufacturing of third-party CAR T-cell immunotherapies against arbitrary targets. As such, CAR T-cell immunotherapies can therefore be used in an "off-the-shelf" manner akin to other biologic immunopharmaceuticals
Key Findings
1
A scalable manufacturing process produces T cells lacking both the αβ T-cell receptor and CD52.
2
Adding a CD19 CAR enables efficient killing of CD19-positive tumor targets despite chemotherapy, supporting third-party, off-the-shelf CAR T-cell immunotherapies.
3
Alemtuzumab administered concurrently with or before engineered T cells can support their engraftment because the cells resist depletion.
4
Electroporation of TALEN mRNA enables highly efficient multiplex genome editing in primary human T cells.
5
TCR-deficient engineered T cells do not mediate graft-versus-host reactions, while CD52 deficiency confers resistance to alemtuzumab-mediated destruction.
Research Object
large-scale manufactured allogeneic human CAR T cells with multiplex TALEN-mediated disruption of the αβ T-cell receptor and CD52
Research Subject
their graft-versus-host reactivity, resistance to alemtuzumab-mediated destruction, engraftment, and CD19-positive tumor-killing function for off-the-shelf adoptive immunotherapy
Publication Details
Publication Date
2015-07-16
Journal
Publisher
ISSN
Cited by
651
Access Type
Author Information
Download PDF
Subscribe to digest
Cited by4
Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects2020
High-throughput continuous-flow microfluidic electroporation of mRNA into primary human T cells for applications in cellular therapy manufacturing2020
Optimization of electroporation and other non‐viral gene delivery strategies for T cells2020
Optimized two‐step electroporation process to achieve efficient nonviral‐mediated gene insertion into primary T cells2021